Medical Cannabis Driving: DVLA Issues New Patient Guidance

The Driver and Vehicle Licensing Agency (DVLA) has published revised guidance aimed specifically at patients who are prescribed cannabis-based medicines and wish to understand their legal position when driving. The guidance addresses a frequently asked question among UK medical cannabis patients and provides clearer information on how prescribed cannabis interacts with road traffic law and the drug drive offence threshold.

The Current Legal Position

Under UK road traffic law, it is a criminal offence to drive with a blood-serum concentration of delta-9-THC above 2 micrograms per litre. This threshold applies regardless of whether the THC was consumed via a lawful prescription or otherwise. The law does not provide an explicit statutory medical defence for THC in the same way it does for certain other prescribed substances.

However, a "medical defence" may be available to patients who can demonstrate that their THC blood concentration was within the therapeutic range for their prescription and that their driving was not impaired. This defence requires prescribers to provide clear documentation to patients.

Key Points from the DVLA Guidance

• Patients prescribed THC-containing products should carry documentation from their prescriber at all times when driving
• The 2 microgram per litre blood-THC limit still applies to medical patients
• High-CBD, low-THC products (below 0.2% THC) are less likely to result in a positive roadside test
• Patients should not drive within four to six hours of taking a THC-containing product without medical guidance
• Prescribers are encouraged to advise patients specifically on driving and provide written documentation of their prescription

Advice for Patients

The safest approach for patients prescribed THC-containing medicines is to speak frankly with their prescribing specialist about driving. Many clinics now routinely provide a standard letter that patients can carry in their vehicle confirming their prescription details and diagnosis.

Patients using CBD-dominant products with minimal THC content are generally at much lower risk of a positive roadside test, though they should still seek prescriber guidance on this issue. For product-specific cannabinoid information, visit our strain database or review the detailed profiles in our products section.

Getting Further Advice

Patients with specific concerns about driving and their medical cannabis prescription should raise the matter directly with their clinic. Our clinic directory lists all major UK providers, many of whom offer dedicated advice sessions on lifestyle and legal considerations for patients.